Navegar por autor "García Campelo, María del Rosario"

10(th) Congress on Lung Cancer-updates on clinical trials: goal

2014- García Campelo, María del Rosario

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

2015- García Campelo, María del Rosario

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

2014- Abdulkader Nallib, Ihab; García Campelo, María del Rosario

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

2020- Viñolas, N Nuria; García Campelo, María del Rosario; Majem, Margarita; Carcereny, Enric; Isla, Dolores; [et al.]

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations

2011- García Campelo, María del Rosario

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

2015- García Campelo, María del Rosario

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)

2015- García Campelo, María del Rosario; Alonso-Jaudenes Curbera, Guillermo

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

2019- Califano, R; Hochmair, M J; Gridelli, C; Delmonte, A; García Campelo, María del Rosario; [et al.]

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

2020- Camidge, D Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C H; Han, Ji-Youn; [et al.]

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

2019- Zugazagoitia, J; Ramos, I; Trigo, J M; Palka, M; Gomez-Rueda, A; [et al.]

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

2021- Filippi, Andrea R; Dziadziuszko, Rafał; García Campelo, María del Rosario; Paoli, Jean-Baptiste; Sawyer, William; [et al.]

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

2019- Angelats L; García Campelo, María del Rosario; Bernabe Caro R; Arriola Aperribay E; Calvo de Juan V; [et al.]

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

2012- García Campelo, María del Rosario

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019- RUIZ BAÑOBRE, JUAN; Areses Manrique, María Carmen; Mosquera-Martinez, J.; Cortegoso Mosquera, Alexandra Sabela; Afonso-Afonso, F. J.; [et al.]

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

2011- Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; Fernández Calvo, Ovidio; [et al.]

Fructose transporter GLUT5 expression in clear renal cell carcinoma

2011- Valladares Ayerbes, Manuel; Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; Santamarina Cainzos, Isabel; [et al.]

Hierarchical clustering analysis of tissue microarray immunostaining data on renal cell carcinomas

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Antón Aparicio, Luis Miguel; Aparicio Gallego, Guadalupe; Medina Villaamil, Vanessa; [et al.]

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

2020- Riudavets, Mariona; Mosquera Martínez, Joaquín; García Campelo, María del Rosario; Serra, Jorgina; Anguera, Georgia; [et al.]

Impact of advanced or metastatic non-small cell lung cancer symptoms on patient daily living and health related quality of life

2011- García Campelo, María del Rosario

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

2020- Remon, J; García Campelo, María del Rosario; de Álava, E; Vera, R; Rodríguez-Peralto, J L; [et al.]

Repositorio digital RUNA

Navegar por autor "García Campelo, María del Rosario"

10(th) Congress on Lung Cancer-updates on clinical trials: goal ﻿

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease ﻿

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry ﻿

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study ﻿

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations ﻿

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer ﻿

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) ﻿

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial ﻿

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial ﻿

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping ﻿

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy ﻿

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) ﻿

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial ﻿

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy ﻿

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study ﻿

Fructose transporter GLUT5 expression in clear renal cell carcinoma ﻿

Hierarchical clustering analysis of tissue microarray immunostaining data on renal cell carcinomas ﻿

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents ﻿

Impact of advanced or metastatic non-small cell lung cancer symptoms on patient daily living and health related quality of life ﻿

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology ﻿

10(th) Congress on Lung Cancer-updates on clinical trials: goal

A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

Fructose transporter GLUT5 expression in clear renal cell carcinoma

Hierarchical clustering analysis of tissue microarray immunostaining data on renal cell carcinomas

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Impact of advanced or metastatic non-small cell lung cancer symptoms on patient daily living and health related quality of life

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology